KBY Biotech Indexv0.0.34
Search
← Pipeline|Olpasertib

Olpasertib

Phase 3
DFF-3055
By Diffusion Pharma
Source: Trial-derived·Trials: 1
Modality
Radioligand
MOA
BTKi
Target
DLL3
Pathway
Sphingolipid
NBOCDAML
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
~Apr 2022
→ ~Jul 2023
Phase 3
Oct 2023
→ Apr 2027
Phase 3Current
NCT03497681
1,068 pts·NB
2023-10→2027-04·Not yet recruiting
1,068 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-04-101.0y awayPh3 Readout· NB
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P3
Not yet…
Catalysts
Ph3 Readout
2027-04-10 · 1.0y away
NB
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03497681Phase 3NBNot yet recr...1068LiverFat
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-7809PfizerPhase 1DLL3HER2
PexarelsinAstraZenecaPhase 1DLL3KRASG12Di
AZN-8281AstraZenecaPhase 1SHP2BTKi
BMY-3371Bristol-Myers SquibbPhase 3WRNBTKi
ZorivorutinibBristol-Myers SquibbApprovedDLL3Cl18.2
NVO-7872Novo NordiskNDA/BLAB7-H3BTKi
NVO-6275Novo NordiskPhase 1SMN2BTKi
ZanumavacamtenGSKPhase 2/3TROP-2BTKi
ZenonesiranGSKPreclinicalDLL3CD47i
TAK-2403TakedaPhase 2WEE1BTKi